Can engineered immune cells tame autoimmune kidney disease?
NCT ID NCT07746453
First seen Aug 05, 2026 · Last updated Aug 11, 2026 · Updated 3 times
Summary
This early-stage trial is testing whether a single infusion of universal STAR-T cells—a type of engineered immune cell that targets both CD19 and BCMA—can safely and effectively treat two autoimmune kidney diseases: IgA nephropathy and primary membranous nephropathy. The study will enroll about 10 to 24 adults and will test three different dose levels to find the safest and most promising dose. The main goals are to see if the treatment can reduce protein in the urine (a sign of kidney damage) and to monitor for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Universal STAR-T cells (CD19 and BCMA bispecific CAR-T cells) given as a single intravenous infusion
- What this could lead to
- If successful, this could offer a new way to treat autoimmune kidney diseases by resetting the immune system, potentially reducing or eliminating the need for long-term immunosuppression.
- What could go wrong
- This is an early, small exploratory study. The therapy may not work for all participants, and CAR-T cell treatments carry risks like cytokine release syndrome, infections, and other serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY (IGAN) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guangdong Provincial People's Hospital.
Guangdong, Guangzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells tackle a tough kidney disease?
- Can a smarter antibody outsmart a kidney disease that resists standard treatment?
- Can a pill calm the immune attack on kidneys?
- Can a gene-silencing drug calm overactive complement in kidney disease?
- Can an Anti-Inflammatory diet protect the kidneys? a trial puts the autoimmune protocol to the test
- Atacicept's Long-Term promise for kidney disease